A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) (NCT06340360)
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
🩺 Plain-English Summary (8th-Grade Level)
This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, an optional 16-week treatment extension period, and a 24-week follow-up period. The maximum study duration is approximately 81 weeks for all participants.
Who can join: Review the eligibility criteria below.
Location: Nektar Investigative Site — Northridge, California
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Nektar Investigative Site — Northridge, California
- Nektar Investigative Site — Atlanta, Georgia
- Nektar Investigative Site — Gurnee, Illinois
- Nektar Investigative Site — Indianapolis, Indiana
- Nektar Investigative Site — Clinton Township, Michigan
- Nektar Investigative Site — Portsmouth, New Hampshire
- Nektar Investigative Site — New York, New York
- Nektar Investigative Site — Camp Hill, Pennsylvania
- Nektar Investigative Site — Frisco, Texas
- Nektar Investigative Site — Pflugerville, Texas
- Nektar Investigative Site — Surrey, British Columbia
- Nektar Investigative Site — Markham, Ontario
- Nektar Investigative Site — Oakville, Ontario
- Nektar Investigative Site — Richmond Hill, Ontario
- Nektar Investigative Site — Sherbrooke, Quebec
- Nektar Investigative Site — Wroclaw, Lower Silesian Voivodeship
- Nektar Investigative Site — Wroclaw, Lower Silesian Voivodeship
- Nektar Investigative Site — Wroclaw, Lower Silesian Voivodeship
- Nektar Investigative Site — Nowa Sól, Lubusz Voivodeship
- Nektar Investigative Site — Warsaw, Masovian Voivodeship
- Nektar Investigative Site — Warsaw, Masovian Voivodeship
- Nektar Investigative Site — Gdansk, Pomeranian Voivodeship
- Nektar Investigative Site — Katowice, Silesian Voivodeship
- Nektar Investigative Site — Sosnowiec, Silesian Voivodeship
- Nektar Investigative Site — Olsztyn, Warmian-Masurian Voivodeship
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alopecia Areata
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Birmingham, Alabama
- A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo — Northridge, California
- Alopecia Areata Registry — San Francisco, California
- Intralesional Cyclosporine for Alopecia Areata — Sacramento, California
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) — Scottsdale, Arizona
Explore by condition: All Alopecia Areata clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.